STOCK TITAN

Nano-X Imaging Ltd. - $NNOX STOCK NEWS

Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: $NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.

NANO-X IMAGING LTD (Nasdaq: NNOX) is at the forefront of revolutionizing medical imaging through its cutting-edge nanotechnology. The company is developing the next generation of X-ray emitters that aim to bring X-ray imaging into the digital era. Its primary offering, the Nanox System, is a combination of hardware and software designed to enhance and modernize medical imaging.

The key component of this system is the Nanox.ARC, a digital X-ray source that incorporates novel nanotechnology to create detailed 3D images. Accompanying this is the Nanox.CLOUD, a cloud-based software platform that enables the delivery of medical screening as a service.

Nano X Imaging Ltd has made significant strides with its Nanox.AI subsidiary, which focuses on deep-learning medical imaging analytics. This arm of the company leverages AI technology to extract valuable clinical insights from routine medical imaging, facilitating early detection and preventative care pathways for patients globally.

One of the latest achievements includes a remarkable study conducted in partnership with the NHS under the Falls and Fragility Fracture Audit Programme (FFFAP). The study revealed a substantial increase in patient identification for spine fractures using the Nanox.AI algorithm, surpassing the national average by up to sixfold. This success highlights the potential of AI-powered solutions in early diagnosis and improved patient care.

Moreover, Nanox has been actively involved in enhancing its AI capabilities with the development of HealthVCF and its updated version HealthOST, both of which received FDA 510(K) clearance. These AI tools focus on highlighting low bone mineral density and measuring the severity of vertebral compression fractures, thus playing a crucial role in osteoporosis management.

The company also offers Second Opinions, an online medical consultation service through its subsidiary USARAD Holdings INC. This platform integrates Nanox.AI's FDA-cleared AI solutions, allowing patients to gain second opinions from medical experts, promoting early detection and preventive management of chronic conditions.

By providing accessible and affordable diagnostic tools, Nanox's vision is to improve early detection and treatment, thereby enhancing global health outcomes and saving lives. The company's comprehensive ecosystem—including Nanox.ARC, Nanox.AI, Nanox.CLOUD, and USARAD's teleradiology services—creates an innovative network connecting medical imaging solutions from scan to diagnosis.

Rhea-AI Summary

Nano-X Imaging announced the integration of AI solutions into its Second Opinions platform, enhancing its teleradiology services. This advancement leverages deep-learning AI from Nanox.AI to analyze chest and abdominal CT scans, aiming to detect chronic conditions early. The platform, managed by USARAD Holdings, now includes FDA-cleared AI tools: HealthCCSng for coronary artery disease, HealthOST for osteoporosis risk, and HealthFLD for fatty liver disease. These AI findings are vetted by physicians and integrated into patient reports.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
none
-
Rhea-AI Summary

Nanox Imaging announced its Q1 2024 financial results, reporting revenues of $2.6 million, up from $2.4 million in Q1 2023. However, the net loss increased to $12.2 million from $11.8 million in the previous year. The company secured agreements with Dandelion Health and Covera Health for its AI solutions and demonstrated its Nanox.ARC scanning technology in New Jersey. Nanox also entered a partnership with Swissray to improve customer support. Despite a decrease in research and administrative expenses, gross loss increased significantly. Cash reserves dropped to $73.3 million from $82.8 million at the end of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary

Nanox Imaging, a medical imaging technology company, will announce its financial results for Q1 2024 on May 28, 2024. The report, covering the period ending March 31, 2024, will be released before the market opens. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET to review the results and provide a business update. Interested parties can register for the call or access the live webcast via links available on Nanox's Investor Relations section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
conferences earnings
Rhea-AI Summary

NANO-X IMAGING , the innovative medical imaging technology company, announced that its teleradiology subsidiary, USARAD Holdings, Inc., has been awarded The Joint Commission's Gold Seal of Approval for Ambulatory Health Care Accreditation for the sixth time. This accreditation reflects the organization's commitment to safe and quality patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
Rhea-AI Summary

Nanox, a medical imaging technology company, is set to participate in three investor conferences in May 2024. The conferences include EF Hutton 2024 Annual Global Conference, AGP 2024 Healthcare Conference, and Benchmark 2024 Healthcare House Call Virtual Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences
-
Rhea-AI Summary
NANO-X IMAGING (NNOX) filed its 2023 Annual Report on Form 20-F with the SEC, including audited financial statements. Shareholders can access the report on the SEC and company websites. Hard copies are available upon request.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
Rhea-AI Summary
Nanox partners with AhealthZ and SCL Science to advance Nanox.ARC 3D imaging system and AI solutions in South Korea, aiming to secure local authorizations and licenses. The collaboration includes integration of Nanox's AI solutions in remote image analysis and potential integration of Nanox.MARKETPLACE with SCL Science's teleradiology centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
Rhea-AI Summary
Nanox launches Nanox.ARC in the United States with installations across five states, marking a major advancement in medical imaging management. The company generated $2.4 million in revenue in Q4 2023, showing growth from the previous year. Nanox.ARC systems have begun scanning patients in the US and passed required tests in three states. Nanox.AI secured FDA clearance for HealthFLD, an AI-based software for fatty liver disease assessment. The ADOPT study demonstrated a sixfold increase in identifying patients with vertebral compression fracture. Nanox continues to advance in clinical trials and regulatory processes, aiming to provide transformative healthcare solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
-
Rhea-AI Summary
NANO-X IMAGING (NNOX) will report its financial results for Q4 and fiscal year 2023 on April 1, 2024. The CEO and CFO will host a conference call to discuss the results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.57%
Tags
conferences earnings
Rhea-AI Summary
NANO-X IMAGING LTD (NNOX) and Nanox.AI announce early findings from the ADOPT study, showing significant improvement in detecting vertebral compression fractures using AI technology in routine CT scans. The study identified up to six times more patients with spine fractures than the UK national average, leading to better patient outcomes and potential cost savings for healthcare systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
AI

FAQ

What is NANO-X IMAGING LTD?

NANO-X IMAGING LTD is a company specializing in the development and manufacturing of advanced medical imaging systems using nanotechnology.

What are the main products of NANO-X IMAGING LTD?

The company offers the Nanox System, which includes the Nanox.ARC, a digital X-ray imaging system, and Nanox.CLOUD, a cloud-based platform for medical screening.

What is the Nanox.AI subsidiary?

Nanox.AI is a subsidiary focused on deep-learning medical imaging analytics, leveraging AI to extract clinical insights from routine imaging and facilitating early diagnosis.

What recent achievements has Nanox reported?

Nanox has reported significant improvements in patient identification for spine fractures through the NHS FFFAP study and has developed AI tools like HealthVCF and HealthOST.

What is HealthOST?

HealthOST is an updated AI tool by Nanox that highlights low bone mineral density and measures the severity of vertebral compression fractures, aiding osteoporosis management.

What is Second Opinions?

Second Opinions is an online medical consultation service provided by USARAD Holdings INC, a subsidiary of Nanox, offering second opinions from medical specialists.

How does Nanox aim to improve global health outcomes?

Nanox aims to improve global health outcomes by providing accessible and affordable diagnostic tools that enhance early detection and treatment of diseases.

What is the significance of the Nanox.ARC?

Nanox.ARC is a digital X-ray source that uses nanotechnology to create detailed 3D images, advancing the field of medical imaging with its innovative approach.

How does Nanox.CLOUD contribute to the Nanox System?

Nanox.CLOUD is a companion software platform that enables the delivery of medical screening as a service, making the Nanox System more efficient and user-friendly.

What are some of the benefits of using Nanox.AI's solutions?

Nanox.AI's solutions help clinicians extract actionable clinical insights from routine imaging, facilitating early diagnosis, preventive care, and potentially improving patient outcomes.

Nano-X Imaging Ltd.

Nasdaq:NNOX

NNOX Rankings

NNOX Stock Data

439.77M
55.12M
9.13%
22.76%
15.35%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Neve Ilan